Cargando…
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we s...
Autores principales: | Tun, Aung M., Khurana, Arushi, Mwangi, Raphael, Link, Brian K., Wang, Yucai, Feldman, Andrew L., Thompson, Carrie A., Novak, Anne J., Villasboas, Jose C., Thanarajasingam, Gita, Farooq, Umar, Syrbu, Sergei, Nowakowski, Grzegorz S., Witzig, Thomas E., Ansell, Stephen M., Rimsza, Lisa M., Cerhan, James R., Habermann, Thomas M., Maurer, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631639/ https://www.ncbi.nlm.nih.gov/pubmed/35849723 http://dx.doi.org/10.1182/bloodadvances.2022007990 |
Ejemplares similares
-
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022) -
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022) -
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022) -
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021) -
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)